Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have earned an average recommendation of "Buy" from the eight ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $13.71.

HUMA has been the topic of a number of recent research reports. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a "neutral" rating in a research note on Friday, October 18th. Benchmark increased their price objective on Humacyte from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Monday, December 23rd. BTIG Research reissued a "buy" rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. TD Cowen reaffirmed a "buy" rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Finally, D. Boral Capital reissued a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Monday.

Insider Buying and Selling at Humacyte

In other news, CEO Laura E. Niklason sold 811,172 shares of the firm's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the sale, the chief executive officer now directly owns 2,419,712 shares of the company's stock, valued at $10,743,521.28. This trade represents a 25.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the business's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares of the company's stock, valued at $8,646,378.02. This represents a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,500,000 shares of company stock worth $6,606,799 over the last ninety days. Company insiders own 11.20% of the company's stock.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its holdings in shares of Humacyte by 62.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company's stock worth $1,219,000 after acquiring an additional 97,931 shares during the period. Principal Financial Group Inc. bought a new stake in shares of Humacyte during the 2nd quarter valued at $83,000. Rhumbline Advisers raised its holdings in Humacyte by 87.8% in the second quarter. Rhumbline Advisers now owns 110,919 shares of the company's stock worth $532,000 after purchasing an additional 51,858 shares during the period. Renaissance Technologies LLC raised its position in shares of Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company's stock worth $2,881,000 after purchasing an additional 524,600 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Humacyte in the second quarter valued at approximately $110,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Humacyte Price Performance

NASDAQ HUMA traded down $0.22 during trading hours on Monday, hitting $4.39. 2,870,027 shares of the company's stock traded hands, compared to its average volume of 3,627,962. The company has a market capitalization of $552.52 million, a PE ratio of -3.28 and a beta of 1.32. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. Humacyte has a 52-week low of $2.48 and a 52-week high of $9.97. The firm's 50-day moving average is $4.67 and its 200-day moving average is $5.69.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.